Haleon PLC Executes Share Buyback to Enhance Shareholder Value

Haleon PLC ( (GB:HLN) ) just unveiled an update.

Haleon PLC announced the purchase and cancellation of 1,011,111 ordinary shares as part of its share buyback program, which was initiated on March 28, 2025. This transaction reflects Haleon’s strategic financial management, potentially enhancing shareholder value by reducing the number of shares in circulation. The company’s registered share capital now stands at 8,992,573,595 ordinary shares, with 8,988,493,390 shares holding voting rights, which may affect shareholder notifications under regulatory guidelines.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Spark’s Take on GB:HLN Stock

According to Spark, TipRanks’ AI Analyst, GB:HLN is a Neutral.

Haleon PLC’s overall stock score reflects a strong financial foundation and strategic initiatives like share buybacks contributing positively to shareholder value. However, technical indicators suggest bearish trends, and the relatively high P/E ratio raises valuation concerns. The company’s confidence in its growth outlook, despite some market challenges, provides additional strength to its stock position.

To see Spark’s full report on GB:HLN stock, click here.

More about Haleon PLC

Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company’s product portfolio includes Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Its brands, such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren, are known for their trusted science and innovation.

Average Trading Volume: 26,171,480

Technical Sentiment Signal: Buy

Current Market Cap: £34.55B

Find detailed analytics on HLN stock on TipRanks’ Stock Analysis page.